Adrian Hargrave, CEO of SEEEN, explains how the Company is now funded through to profitability.  Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 323.50
Bid: 323.50
Ask: 325.50
Change: -10.00 (-3.00%)
Spread: 2.00 (0.618%)
Open: 328.00
High: 328.00
Low: 323.50
Prev. Close: 333.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

30 Apr 2019 17:38

RNS Number : 6433X
Oxford Biomedica PLC
30 April 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oxford Biomedica PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Oaktree Capital Group Holdings GP, LLC

City and country of registered office (if applicable)

333 South Grand Ave., 28th Floor Los Angeles, CA 90071, U.S.A.

4. Full name of shareholder(s) (if different from 3.)v

Name

OCM Strategic Credit Investments S.A R.L.

Name

OCM Strategic Credit Investments 2 S.A R.L.

Name

OCM Luxembourg SC Fund A S.A R.L.

Name

OCM Luxembourg SC Fund B S.A R.L.

City and country of registered office (if applicable)

26A boulevard Royal, 7th Floor, L-2449Luxembourg

5. Date on which the threshold was crossed or reachedvi:

26 April 2019

6. Date on which issuer notified (DD/MM/YYYY):

30 April 2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.91%

N/A

3.91%

68,860,324

Position of previous notification (if

applicable)

 

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares

0

2,689,686

0.00%

3.91%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

2,689,686

3.91%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

N/A

N/A

N/A

N/A

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Oaktree Capital Group Holdings GP, LLC

 

 

 

Oaktree Capital Group, LLC

 

 

 

Oaktree Holdings, Inc.

 

 

 

Oaktree CapitalManagement, L.P.

 

 

 

Oaktree-TCDRSStrategic Credit, LLC

 

 

 

Oaktree-TSE 16Strategic Credit, LLC

 

 

 

Oaktree StrategicIncome, LLC

 

 

 

INPRS Strategic Credit Holdings, LLC

 

 

 

OCM Strategic Credit Investments S.A R.L.[1]

1.103%

 

 

 

 

 

 

Oaktree Capital Group Holdings GP, LLC

 

 

 

Oaktree Capital Group, LLC

 

 

 

Oaktree Holdings, Inc.

 

 

 

Oaktree CapitalManagement, L.P.

 

 

 

Exelon Strategic Credit Holdings, LLC

 

 

 

Oaktree-NGP Strategic Credit, LLC

 

 

 

Oaktree-Minn Strategic Credit, LLC

 

 

 

Oaktree-ForestMulti-Strategy, LLC (Series A)

 

 

 

Oaktree-TBMR Strategic Credit Fund C, LLC

 

 

 

Oaktree-TBMR Strategic Credit Fund F, LLC

 

 

 

Oaktree-TBMR Strategic Credit Fund G, LLC

 

 

 

OCM Strategic Credit Investments 2 S.A R.L.[2]

2.065%

 

 

 

 

 

 

Oaktree Capital Group Holdings GP, LLC

 

 

 

Oaktree Capital Group, LLC

 

 

 

Oaktree Holdings, Inc.

 

 

 

Oaktree CapitalManagement, L.P.

 

 

 

Oaktree Capital II, L.P.

 

 

 

Oaktree Fund GP II, L.P.

 

 

 

Oaktree Fund GP IIA, LLC

 

 

 

Oaktree Strategic Credit Fund A GP, L.P.

 

 

 

Oaktree Strategic Credit Fund A, L.P.

 

 

 

OCM Luxembourg SC Fund A S.A R.L.

0.164%

 

 

 

 

 

 

Oaktree Capital Group Holdings GP, LLC

 

 

 

Oaktree Capital Group, LLC

 

 

 

Oaktree Holdings, Inc.

 

 

 

Oaktree Capital Management, L.P.

 

 

 

Oaktree Capital II, L.P.

 

 

 

Oaktree Fund GP II, L.P.

 

 

 

Oaktree Fund GP IIA, LLC

 

 

 

Oaktree Strategic Credit Fund B GP, L.P.

 

 

 

Oaktree Strategic Credit Fund B, L.P.

 

 

 

OCM Luxembourg SC Fund B SP 1, L.P.

 

 

 

OCM Luxembourg SC Fund B S.A R.L.

0.572%

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional information

 

     

 

Place of completion

London, United Kingdom

Date of completion

30 April 2019

 

Contact name:

Stuart Paynter

Contact telephone number:

01865 783000

 

 

[1] Oaktree-TCDRS Strategic Credit, LLC, Oaktree-TSE 16 Strategic Credit, LLC, Oaktree Strategic Income, LLC and INPRS Strategic Credit Holdings, LLC jointly control OCM Strategic Credit Investments S.A R.L.

[2] Exelon Strategic Credit Holdings, LLC, Oaktree-NGP Strategic Credit, LLC, Oaktree-Minn Strategic Credit, LLC, Oaktree-Forest Multi-Strategy, LLC (Series A), Oaktree-TBMR Strategic Credit Fund C, LLC, Oaktree-TBMR Strategic Credit Fund F, LLC, and Oaktree-TBMR Strategic Credit Fund G, LLC jointly control OCM Strategic Credit Investments 2 S.A R.L..

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAKLEDDKNEFF
Date   Source Headline
3rd May 202210:35 amRNSTotal Voting Rights
29th Apr 20225:42 pmRNSDirectors Dealings / Market Share Purchases
28th Apr 20222:24 pmRNSDirector/PDMR Shareholding
27th Apr 20222:58 pmRNS2021 Annual report and accounts & AGM notification
27th Apr 202212:10 pmRNSPDMR Dealings / Market Share Purchase
21st Apr 20224:41 pmRNSDirector Share Purchase
21st Apr 20221:24 pmRNSDirectors Dealings / Market Share Purchase
21st Apr 202210:16 amRNSDirector/PDMR Shareholding
20th Apr 20223:45 pmRNSDirector/PDMR Shareholding
20th Apr 20227:00 amRNSPreliminary Results
13th Apr 20227:00 amRNSBoard Appointment
4th Apr 202211:34 amRNSNotice of Preliminary Results
1st Apr 20226:30 pmRNSHolding(s) in Company
1st Apr 202210:33 amRNSBlock listing Application
1st Apr 20229:34 amRNSTotal Voting Rights
31st Mar 20226:07 pmRNSHolding(s) in Company
30th Mar 20221:00 pmRNSHolding(s) in Company
25th Mar 20225:15 pmRNSHolding(s) in Company
21st Mar 202210:44 amRNSLong Term Incentive Plan Option Grant
15th Mar 202211:25 amRNSHolding(s) in Company
15th Mar 20229:39 amRNSHolding(s) in Company
11th Mar 20224:51 pmRNSHolding(s) in Company
11th Mar 20229:01 amRNSAdmission of Conditional Placing Shares
10th Mar 20225:32 pmRNSCompletion of Transaction
9th Mar 202211:42 amRNSDirector Declaration
8th Mar 20223:54 pmRNSResult of General Meeting
1st Mar 20229:52 amRNSTotal Voting Rights
16th Feb 202211:41 amRNSPublication of Circular & Notice of GM
4th Feb 20228:22 amRNSAdmission of Firm Placing Shares
1st Feb 20229:06 amRNSTotal Voting Rights
1st Feb 20227:00 amRNSUpdate to agreement with Sio Gene Therapies
31st Jan 202211:21 amRNSMarket Share Purchase
28th Jan 20225:59 pmRNSResult of Placing and PrimaryBid offer
28th Jan 20222:04 pmRNSHoldings in Company
28th Jan 20227:38 amRNSRetail offer by PrimaryBid
28th Jan 20227:24 amRNSUS Agreement and Proposed Placing of Shares
17th Jan 20227:00 amRNSJohn Dawson to retire from Oxford Biomedica
5th Jan 20227:00 amRNSOxford Biomedica Agreement with Cabaletta Bio
4th Jan 202211:07 amRNSBlock listing Return
4th Jan 202210:32 amRNSTotal Voting Rights
4th Jan 20227:00 amRNSJohn Dawson awarded CBE in New Year Honours List
14th Dec 20217:00 amRNSBoard Appointment
13th Dec 20217:00 amRNSOxford Biomedica Updates Lentiviral Agreement
13th Dec 20217:00 amRNSOxford Biomedica Signs Agreement with Arcellx
1st Dec 20219:49 amRNSTotal Voting Rights
1st Nov 202110:08 amRNSLong Term Incentive Plan Option Grant
1st Nov 202110:02 amRNSTotal Voting Rights
19th Oct 20217:00 amRNSBoehringer Ingelheim Exercises Option
1st Oct 20219:51 amRNSTotal Voting Rights
29th Sep 20215:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.